Scorpius Holdings Beheer

Beheer criteriumcontroles 4/4

De CEO Scorpius Holdings is Jeff Wolf, benoemd in Aug2008, heeft een ambtstermijn van 16.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 575.00K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.58% van de aandelen van het bedrijf, ter waarde € 13.93K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 7.7 jaar.

Belangrijke informatie

Jeff Wolf

Algemeen directeur

US$575.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	16.1yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jeff Wolf's beloning veranderd ten opzichte van Scorpius Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$575k	US$575k	-US$40m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	n/a	n/a	-US$50m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$3m	US$562k	-US$41m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$36m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$6m	US$540k	-US$35m
Sep 30 2021	n/a	n/a	-US$28m
Jun 30 2021	n/a	n/a	-US$29m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$6m	US$440k	-US$26m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$21m
Dec 31 2019	US$3m	US$428k	-US$20m
Sep 30 2019	n/a	n/a	-US$22m
Jun 30 2019	n/a	n/a	-US$19m
Mar 31 2019	n/a	n/a	-US$18m
Dec 31 2018	US$1m	US$417k	-US$16m
Sep 30 2018	n/a	n/a	-US$14m
Jun 30 2018	n/a	n/a	-US$13m
Mar 31 2018	n/a	n/a	-US$12m
Dec 31 2017	US$964k	US$417k	-US$12m

Compensatie versus markt: De totale vergoeding ($USD 575.00K ) Jeff } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).

Compensatie versus inkomsten: De vergoeding van Jeff is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jeff Wolf (61 yo)

16.1yrs

Tenure

US$575,000

Compensatie

Mr. Jeffrey Alan Wolf, also known as Jeff, J.D. founded Scorpius Holdings, Inc. (formerly known as NightHawk Biosciences, Inc.) (formerly known as Heat Biologics, Inc.) in August 2008 and has been Chairman...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Wolf	Founder	16.1yrs	US$575.00k	0.58% € 13.9k
William Ostrander	CFO, Controller & Secretary	5yrs	US$375.00k	0.0010% € 24.7
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
George Peoples	Chief Medical Advisor	7.4yrs	geen gegevens	geen gegevens
Ania Szymanska	Site Head of Quality	less than a year	geen gegevens	geen gegevens
Joe Payne	President & COO of Scorpius BioManufacturing	less than a year	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

Ervaren management: Het managementteam van 1HB0 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Wolf	Founder	16.1yrs	US$575.00k	0.58% € 13.9k
Justin Stebbing	Chief Medical Advisor and Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
John K. Prendergast	Independent Lead Director	8.4yrs	US$301.00k	0.038% € 916.3
John Monahan	Independent Director	14.8yrs	US$81.50k	0% € 0
Llew Keltner	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Anthony Tolcher	Scientific Advisory Board Member	6.5yrs	geen gegevens	geen gegevens
Roger Cohen	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Richard Myers	Chairman of BioThreat Advisory Board	2.3yrs	geen gegevens	geen gegevens
Gary Acton	Member of Scientific & Clinical Advisory Board	no data	geen gegevens	geen gegevens
Robert Negrin	Member of Scientific Advisory Board	6.9yrs	geen gegevens	geen gegevens
Edward Smith	Independent Director	13.8yrs	US$92.50k	0% € 0
Robert Levy	Member of Scientific Advisory Board	6.9yrs	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 1HB0 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

Scorpius Holdings Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Recent updates

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

NYSE American Withdraws Delisting Determination of Scorpius Holdings Common Stock

Scorpius Holdings Set to Launch First Mammalian Cgmp Campaign At San Antonio Facility in the 2024 3Rd Quarter

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $12.5 million.

Scorpius Holdings, Inc Successfully Executes First cGMP Microbial Batches at San Antonio Facility

NYSE Determines to Commence Proceedings to Delist Scorpius Holdings' Common Stock from the NYSE American Due to Company No Longer Suitable for Listing Pursuant to Section 1003(f)(v) of the NYSE American Company Guide

Scorpius Holdings, Inc., Annual General Meeting, Jul 19, 2024

Scorpius Holdings, Inc., Annual General Meeting, Aug 02, 2024

Scorpius Holdings, Inc. Provides Non-Compliance Update

Scorpius Holdings, Inc. announced delayed 10-Q filing

Scorpius Holdings, Inc. has completed a Composite Units Offering in the amount of $6 million.

Scorpius Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $11.5 million.

Scorpius Holdings, Inc. announced that it expects to receive $0.75 million in funding from Elusys Holdings Inc.

Scorpius Holdings Regains Compliance with Section 1007 of the NYSE American Company Guide

Scorpius Holdings Announces Receipt of Filing Delinquency Notification

Scorpius Holdings, Inc. announced delayed annual 10-K filing

New minor risk - Shareholder dilution

Scorpius Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 28, 2024

Scorpius Holdings, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Nighthawk Biosciences, Inc. Announces the Promotion of Joe Payne to President and Chief Operating Officer of Its Scorpius Biomanufacturing Subsidiary

NightHawk Biosciences, Inc. Announces Executive Appointments

Jeffrey Wolf acquired Elusys Therapeutics, Inc. from NightHawk Biosciences, Inc. (NYSEAM:NHWK).

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced that it expects to receive $2.25 million in funding

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $4.037193 million.

NightHawk Biosciences, Inc. announced delayed 10-Q filing

NightHawk Biosciences, Inc., Annual General Meeting, Sep 27, 2023

NightHawk Biosciences, Inc., Annual General Meeting, Sep 15, 2022

Richard Myers to Become Chairman of NightHawk's BioThreat Advisory Board

Heat Biologics to Voluntarily Withdraw the Listing of the Company’s Common Stock

Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110

Heat Biologics, Inc. (NasdaqCM:HTBX) executed a definitive merger agreement to acquire Elusys Therapeutics, Inc.

Heat Biologics Unveils RapidVax, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats

Third quarter 2021 earnings released: US$0.30 loss per share (vs US$0.43 loss in 3Q 2020)

Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary

Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2020)

Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients

Heat Biologics, Inc. Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Independent Lead Director recently sold €169k worth of stock

First quarter 2021 earnings released: US$0.31 loss per share (vs US$0.77 loss in 1Q 2020)

Full year 2020 earnings released: US$1.63 loss per share (vs US$4.21 loss in FY 2019)

New 90-day high: €11.05

Heat Biologics, Inc. Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Heat Biologics, Inc. Announces Publication of Additional Preclinical COVID-19 Vaccine Results

Heat Biologics, Inc. Announces the Promotion of William Ostrander to Chief Financial Officer

New 90-day low: €0.79

New 90-day low: €0.81

Third quarter 2020 earnings released: US$0.062 loss per share

Revenue beats expectations

Revenue beats expectations

Third quarter 2020 earnings released: US$0.062 loss per share

Jeff T. Hutchins Leave as A Chief Scientific and Operating Officer from Heat Biologics, Inc

Earnings released

Heat Biologics Regains Compliance with Nasdaq Minimum Bid Price Rule

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd